Replimune Group Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Replimune Group stock.
View analyst ratings for Replimune Group or view top-rated stocks.

Wall Street analysts have given Replimune Group a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Replimune Group wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Replimune Group saw a decline in short interest in the month of May. As of May 28th, there was short interest totaling 2,320,000 shares, a decline of 15.0% from the May 13th total of 2,730,000 shares. Based on an average trading volume of 362,600 shares, the short-interest ratio is currently 6.4 days. Approximately 8.1% of the company's stock are sold short.
View Replimune Group's Short Interest.

Replimune Group is scheduled to release its next quarterly earnings announcement on Friday, August 6th 2021.
View our earnings forecast for Replimune Group.

Replimune Group, Inc. (NASDAQ:REPL) released its quarterly earnings results on Thursday, May, 20th. The company reported ($0.41) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.41).
View Replimune Group's earnings history.

Replimune Group's stock was trading at $11.93 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, REPL shares have increased by 212.6% and is now trading at $37.29.
View which stocks have been most impacted by COVID-19.

8 Wall Street analysts have issued 1-year target prices for Replimune Group's stock. Their forecasts range from $48.00 to $67.00. On average, they anticipate Replimune Group's stock price to reach $56.00 in the next year. This suggests a possible upside of 50.2% from the stock's current price.
View analysts' price targets for Replimune Group or view top-rated stocks among Wall Street analysts.

Some companies that are related to Replimune Group include Halozyme Therapeutics (HALO), Vir Biotechnology (VIR), Twist Bioscience (TWST), Adaptive Biotechnologies (ADPT), Recursion Pharmaceuticals (RXRX), Beam Therapeutics (BEAM), Kodiak Sciences (KOD), Abcam (ABCM), SpringWorks Therapeutics (SWTX), Ablynx (ABLYF), Iovance Biotherapeutics (IOVA), Sana Biotechnology (SANA), Allogene Therapeutics (ALLO), Relay Therapeutics (RLAY) and NanoString Technologies (NSTG).
View all of REPL's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), (BTUUQ) (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC).

(REPL) raised $100 million in an IPO on Friday, July 20th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

Replimune Group trades on the NASDAQ under the ticker symbol "REPL."

Replimune Group's stock is owned by many different retail and institutional investors. Top institutional investors include Omega Fund Management LLC (10.77%), Redmile Group LLC (8.86%), Price T Rowe Associates Inc. MD (6.62%), BlackRock Inc. (4.77%), Ensign Peak Advisors Inc (3.01%) and Corriente Advisors LLC (2.31%). Company insiders that own Replimune Group stock include Colin Love, Fund Iv LP Omega, Jason P Rhodes, Jean M Franchi, Pamela Esposito, Philip Astley-Sparke and Robert Coffin.
View institutional ownership trends for Replimune Group.

REPL stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Corriente Advisors LLC, Millennium Management LLC, Omega Fund Management LLC, Morgan Stanley, Squarepoint Ops LLC, Credit Suisse AG, and Bank of Montreal Can. Company insiders that have sold Replimune Group company stock in the last year include Colin Love, Fund Iv LP Omega, Jason P Rhodes, Jean M Franchi, Pamela Esposito, Philip Astley-Sparke, and Robert Coffin.
View insider buying and selling activity for Replimune Group or view top insider-selling stocks.

REPL stock was bought by a variety of institutional investors in the last quarter, including Loomis Sayles & Co. L P, BVF Inc. IL, Price T Rowe Associates Inc. MD, Tekla Capital Management LLC, Ensign Peak Advisors Inc, Goldman Sachs Group Inc., Redmile Group LLC, and JPMorgan Chase & Co.. Company insiders that have bought Replimune Group stock in the last two years include Fund Iv LP Omega, and Jason P Rhodes.
View insider buying and selling activity for Replimune Group or or view top insider-buying stocks.

Shares of REPL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of REPL stock can currently be purchased for approximately $37.29.

Replimune Group has a market capitalization of $1.74 billion. The company earns $-80,870,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis.

Replimune Group employs 152 workers across the globe.

The official website for Replimune Group is www.replimune.com.

Replimune Group is headquartered at 500 Unicorn Park, WOBURN MA, 01801.

Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The company can be reached via phone at 781-222-9600 or via email at [email protected]